Abstract
monkeys. However, inhibition of PDE4 is generally associated with severe emetic side-effects. 23 Roflumilast, an FDA-approved PDE4 inhibitor for treatment of chronic obstructive pulmonary disease 24 (COPD), is yielding only mild emetic side effects. 25
In the present study we investigate the potential of roflumilast as a cognition enhancer and to 26 determine the potential coinciding emetic response in comparison to rolipram, a classic PDE4 inhibitor 27 with pronounced emetic effects. 28
Cognition enhancement was evaluated in mice and it was found that both roflumilast and rolipram 29 enhanced memory in an object location task (0.03 mg/kg), whereas only roflumilast was effective in a 30 spatial Y-maze (0.1 mg/kg). Emetic potential was measured using competition of PDE4 inhibition for α2-31 adrenergic receptor antagonism in which recovery from xylazine/ketamine-mediated anesthesia is used 32 as a surrogate marker. While rolipram displayed emetic properties at a dose 10 times the memory-33 enhancing dose, roflumilast only showed increased emetic-like properties at a dose 100 times the 34 memory-enhancing dose. Moreover, combining sub-efficacious doses of the approved cognition-35 enhancer donepezil and roflumilast, which did not improve memory when given alone, fully restored 36 object recognition memory deficit in rats induced by the muscarinic receptor antagonist scopolamine. 37 These findings suggest that roflumilast offers a more favorable window for treatment of cognitive 38 deficits compared to rolipram. 39 phosphorylation of the transcription factor cAMP response element binding protein (P-CREB). P-CREB 21 induces expression of CREB responsive genes involved in a wide range of biological functions, such as 22 synaptic plasticity, memory and cognition [2-6], but also inflammation and bronchodilation [7] [8] [9] [10] [11] . 23 24 PDE4 is expressed in the hippocampus and cortex [12, 13] and was also found to remain present in the 25 aged and Alzheimer brain [14, 15] . It can therefore be considered as a promising target for 26 enhancement of cognitive functions. Acute treatment with a PDE4-I clearly improved cognitive functions 27 in healthy and pharmacologically impaired rodents which was particularly investigated using the classic 28 PDE4-I rolipram (e.g. [3, 16] ; for reviews see [17] [18] [19] ). Chronic treatment with rolipram is also beneficial 29 for brain plasticity and cognitive function as was found in age-impaired mice and transgenic mice 30 models of Alzheimer's disease (e.g. [20, 21] ; for reviews see [17, 18] MK-0952 was tested on cognitive impairment in mild to moderate Alzheimer's disease 34 (ClinicalTrials.gov, NCT00362014). However, its announced results [24] have not been disclosed. 35 Currently, HT-0712 is being tested on age-associated memory impairment (ClinicalTrials.gov, 36 NCT02013310). 37 38
Key words
The development of PDE4-Is as therapeutic drugs has been hampered by the dose-limiting emetic side 39 effects (nausea and even vomiting) in humans [25] [26] [27] Because of the reduced emetic properties of roflumilast in humans we explored in the present 21 preclinical study whether roflumilast has the potential to test as a translational cognition enhancer (e.g. 22
ClinicalTrials.gov, NCT01433666). First we determined whether roflumilast improves memory in mice, 23 using the object location test (OLT) and the spatial Y-maze, which are based on the natural tendency of 24 rodents to explore displaced objects and novel spatial environment [37, 38] . As rodents are unable to 25 vomit, we investigated the emetic properties using the xylazine/ketamine-induced anesthesia test. 26 PDE4-Is mimic the pharmacological actions of 2-adrenoceptor antagonists, which has been described 27 as the mechanism by which in particular PDE4D-Is induce emesis [32, 33] . Since 2-adrenoceptor 28 antagonists are also known to reverse xylazine/ketamine-induced anesthesia, the latter effect can be 29 used as a surrogate measure of emesis in rodents [32, 33] . Next, the mice were used for a 30 pharmacokinetic study to verify central availability and biological activity of the PDE4-Is. Finally, we 31 tested the potential beneficial interaction between the acetylcholinesterase inhibitor (AChE-I) donepezil, 32 which is used as a cognition enhancer for the treatment of Alzheimer's disease [39] , and roflumilast on 33 the scopolamine induced memory deficit in rats using the object recognition task (ORT). 34
Materials and Methods

35
Animals 36
All experimental procedures were approved by the local ethical committee of the Maastricht University 37
for animal experiments and met the governmental guidelines and EU guidelines for the care and use of 38 laboratory animals. Twenty-four seven months-old male C57BL/6NCrl mice (Charles River, L'Arbresle, 39
France) were used for the OLT, spatial Y-maze, and xylazine/ketamine induced α2-adrenergic receptor-40 mediated anesthesia test. Average body weight was 27.6 grams at the beginning of the study. Twenty-1 four male Wistar rats were supplied by Charles River (Sulzfeld, Germany) and tested between 3-4 2 months of age in the ORT. Average body weight at the beginning of the study was 345 g. All animals 3 were housed individually in standard individually ventilated cages on sawdust bedding in an air-4 conditioned room (about 21°C). They were kept on a 12/12-h reversed light/dark cycle (lights on from 5
19.00 to 7.00 h) and had free access to food and water. Animals were housed in the same room as 6 where they were tested. A radio, which was playing softly, provided background noise in the room. All 7 testing was done between 9.00 and 18.00 h. All behavioral experiments were performed in a 8 randomized blinded setup. The sample size was calculated based on a power analysis using historical 9 data on rolipram treatment in the object recognition/location task [16, 35, 38] . For the murine studies, 10 all mice were subject chronologically to the object location task, the spatial Y-maze, and 11 xylazine/ketamine test with a one-week-interval between the tasks. 12 13 2. The OLT was performed as described elsewhere [42] . The apparatus consisted of a circular arena, 40 cm 3 in diameter. Half of the 40 cm high transparent polyvinyl chloride wall was covered from the outside 4 with white paper. Two objects were placed symmetrically about 10 cm away from the wall on the 5 separation line, between the transparent and the covered side of the arena. Four different sets of 6 objects were available: (1) a cone made of brass (maximal diameter 6 cm and total height 3.8 cm), (2) a 7 transparent glass bottle (diameter 2.7 cm, height 8.5 cm) filled with sand and water, (3) a massive metal 8 cube (2.5 cm × 5 cm × 7.5 cm) with two holes (diameter 1.5 cm), and (4) a massive aluminium cube with 9 a tapering top (4.5 cm × 4.5 cm × 8.5 cm). Objects and locations were presented to the animals in a 10 balanced manner to avoid object or place biases. A testing session comprised two trials of 4 min. Before 11 each trial, mice were placed in an empty Makrolon cage (incubation cage) for 4 min, to prime their 12 attention. During the first learning trial (T1) two identical objects were placed symmetrically about 10 13 cm away from the wall on the separation line between the transparent and covered side of the arena. 14 After the first exploration period, the mouse was put back in its home cage. Mice then received their 15 treatment 3 h post T1. Subsequently, after the normal forgetting inter-trial interval of 24 h, the mouse 16 was placed in the apparatus for the second trial of 4 min (T2). Two identical objects as in T1 were used; 17 one object was placed in the previously used position, whereas the other was placed in a novel position 18 which could be either a fixed distance towards the front or a fixed distance towards the back of the 19 arena. The times spent exploring each object during T1 and T2 were recorded manually using a personal 20 computer by an experimenter unaware of the conditions being tested. Exploration was defined in the 21 following manner: directing the nose to the object at a distance of no more than 2 cm and/or touching 22 the object with the nose. Sitting on the object was not considered as exploratory behavior. To avoid 23 olfactory cues, the objects were thoroughly cleaned with 70% ethanol after each trial. The testing order 24 of conditions was determined randomly. T1 was always on Monday and Thursday in order to have a 25 sufficient wash-out period between compound sessions. Prior to compound testing, animals were 26 handled daily and adapted to the procedures in two days, i.e. they were allowed to explore the 27 apparatus twice for 3 min each day. All four objects used in this study were presented in these two 28 subsequent days. Thereafter, animals were adapted to the compound administration by one s.c. vehicle 29 injection. 30
The time spent exploring the two identical objects in T1 was indicated as "a1" and "a2", 31
respectively. The time spent exploring the familiar and the new location in T2 was indicated as "a" and 32 "b", respectively. The following variables were calculated: e1 = a1 + a2; e2 = a + b and d2 = (b -a)/e2. e1 33 and e2 are measures of the total exploration time of both objects during T1 and T2, respectively. d2 is a 34 relative measure of discrimination, corrected for exploration activity (e2). This d2 index can range from -35 1 to 1, with 1 indicating complete preference for the novel location/object and 0 signifying no 36 preference for either location/object. Animals with an e1 or e2 lower than 7.5 seconds were excluded 37 since this does not allow to reliably measure memory performance [43] . 38
Spatial Y-maze in mice 39
After completion of the OLT test, the Y-maze spatial memory test was performed using a Y-maze 40 consisting of three equal arms, with each arm being separated from the others at a 120° angle [44, 45] . 41
Each arm was 40 cm long, 17 cm high, 4 cm wide at the bottom and 13 cm wide at the top. In the task, 1 one arm was made inaccessible due to a removable blockade placed in front of the arm during trial one. 2
The blocked arm was randomly alternated among the different trials. In between trials, the maze was 3 cleaned thoroughly with a 70% ethanol solution to reduce olfactory biases. A mouse was placed in one 4 of the open arms (termed the 'start arm', which was randomized over groups) and allowed to explore 5 the two open arms of the maze for 5 min. One arm visit required that both hind paws of the animal had 6 to be placed completely inside the arm. Mice received treatment at 3 h after the first learning trial. After 7 a 24 h interval, the mouse was placed back into its corresponding start arm, but now the blockade had 8 been removed, providing access to the previously blocked arm (termed the 'novel arm'). Spatial memory 9
was assessed by the amount of time spent in the novel arm, which had to be significantly more than 10 33.33%, corrected for the latency to move from the start arm to another arm and the amount of time 11 the animal spent in the center of the maze. The times spent exploring each arm was recorded using 12 Ethovision (Noldus, the Netherlands). Also, the total distance the mouse had travelled in the Y-maze was 13 measured, to rule out any effects caused by differences in activity level. 14 15
Xylazine/ketamine induced α2-adrenergic receptor-mediated anesthesia test in mice 16
Given the emetic properties of PDE4-Is, the ability of roflumilast to shorten xylazine/ketamine induced 17 α2-adrenergic receptor-mediated anesthesia was measured one week after completion of the Y-maze 18 test. Since mice are a non-vomiting species, the xylazine/ketamine anesthesia test, a well-established 19 surrogate marker for emesis in mice, was applied [32] . The earlier the treated mice recover their righting 20 reflex upon anesthesia the more competition there is on the α2-adrenergic receptor. Xylazine (CEVA 21
Santé Animale, Naaldwijk, the Netherlands) (10 mg/kg) and ketamine (Eurovet Animal Health, Bladel, 22 the Netherlands) (60 mg/kg) was given intraperitoneal (i.p.) to induce anesthesia (injection volume: 1.1 23 µl/g) [35] . Rolipram, roflumilast or vehicle were administered 15 min after induction of anesthesia and 24 the mouse was placed in a dorsal position awaiting recovery. The time-delay to the recovery towards 25 the righting reflex (four paws on the floor) was used as an endpoint to measure the time to regain their 26 righting reflex. Animals regaining their righting reflex before the treatment injection or not displaying a 27 righting reflex within 2 h were excluded from analysis. 28
Object recognition in rats 29
Rats were tested in the ORT which was performed as described elsewhere [38, 43] . The apparatus 30 consisted of a circular arena, 83 cm in diameter. The back half of the 40 cm high wall was made of gray 31 polyvinyl chloride (PVC) and the front was made of transparent PVC. Two objects were placed in 32 symmetrical positions at the mid-line between the gray and transparent halves of the arena, about 10 33 cm away from the wall. Four sets of 3 identical objects were used: 1) a standard 1 L brown transparent 34 glass bottle (diameter 10 cm, height 22 cm) filled with water, 2) a metal cube (10.0 x 5.0 x 7.5 cm) with 35 two holes (diameter 1.9 cm), 3) a cone consisting of a gray polyvinyl chloride base (maximal diameter 18 36 cm) with a collar on top made of brass (total height 16 cm), and 4) an aluminum cube with a tapering 37 top (13.0 x 8.0 x 8.0 cm). Objects were presented to the animals in a balanced manner to avoid object or 38 place biases. A test session comprised two trials, each with durations of 3 min. During the learning trial 39 (T1) the apparatus contained two identical objects (object a1 and a2). Subsequently, rats were put back 40 in their home cage for a 1 h interval. After the retention interval, rats were put back into the arena for 41 the test trial (T2). In T2, the two objects from T1 are replaced by one identical copy "a" and a different 42 novel object "b". The times spent in exploring each object during T1 and T2 were recorded manually on 1 a personal computer using the same criteria as for mice. In order to avoid the presence of olfactory 2 cues, the objects were thoroughly cleaned with a 70% ethanol solution before each trial. The 3 discrimination index (d2) was determined as described for mice. Testing was always on Monday, 4
Wednesday or Friday in order to have a sufficient wash-out period between compound sessions. Prior to 5 compound testing, rats were handled and adapted to the procedures and compound administration 6 similarly as with the mice. All rats showed sufficient exploration to have a reliable memory performance 7
[43]. 8
Pharmacokinetics 9
After behavioral testing all mice were subsequently used for the determination of plasma and brain 10 concentrations following s.c. administration. Pharmacokinetic (PK) measurements were expected to be 11 close to the detection limit after dosing with the behaviorally active dose of 0.03 mg/kg of both 12 compounds in the OLT. For this reason doses were increased and animals were sacrificed for blood and 13 brain sampling at 30 min and 21 h after dosing of 0.3 or 3 mg/kg. For rolipram 11 animals were used and 14 for roflumilast 12 animals; n = 3 per time point (except for the 3 mg/kg rolipram condition, n=2). 15
Blood was drawn from the saphenous vein using heparin-coated tubes (Microcuvette CB300, 16 Sarstedt, Germany), which were temporarily stored on ice and then centrifuged within 15 min of 17 collection. Plasma was isolated using centrifugation (1500 g for 10 min at 4°C) and pipetted into vials. 18
Immediately after blood collection the animal was decapitated. The complete brain was collected, 19 rinsed with ice-cold saline, placed in a cup and weighed. Plasma and brain samples were immediately 20 stored at -80°C until analytical processing. Roflumilast, roflumilast-N-oxide and rolipram were quantified 21
by Agilux laboratories (Worcester, USA). Roflumilast-N-oxide was measured in the same samples as 22 roflumilast. For analytical sample preparation, plasma was used as is, while brain samples were first 23 homogenized in 80:20 water:acetonitrile. Both matrices were processed for drug quantification using 24 liquid-liquid extraction methodology followed by a characterized liquid chromatography-tandem mass 25 spectrometry (LC-MS/MS) assay. Standard curves were prepared in control matrices, an appropriate 26 dynamic range was achieved, and instrument settings and potentials were adjusted to optimize the MS 27 signal for the compounds using Masslynx software with the Quanlynx application manager (Waters Ltd). 28
For both roflumilast and rolipram the lowest level of quantification (LLOQ) was 0.5 ng/ml for plasma and 29 1.25 ng/g for brain. If the plasma concentration (Cp) or brain concentration (Cb) of a sample was below 30 the quantification limit (BQL), but one or more of the other samples in the same compound/dose group 31 had measurable values, the BQL was treated as zero. 32
Statistics 33
One-sample t-statistics were performed in order to assess whether the d2 index for each treatment 34 condition differed significantly from zero (chance level) in the OLT or ORT. Effects between treatment 35 conditions were analyzed using a one-way ANOVA, followed by a post-hoc analysis with Dunnett's 36 multiple comparison test. In the Y-maze, one-sample t-statistics were used to assess whether the 37 percentage of time spent in the novel arm for each treatment condition differed significantly from 38 33.33% (chance level). Differences between treatment conditions in the Y-maze were analyzed using a 39 one-way ANOVA followed by Dunnett's multiple comparison test. The latter analysis was also applied in 40 the xylazine/ketamine test. An α level of 0.05 was considered significant. 41
Results
1
Memory 2
In the OLT, the exploration times between treatment conditions for both T1 (e1: F(6,113) = 1.27, n.s.) 3 and T2 (e2: F(6,113) = 1.66, n.s.) were comparable (data not shown). One mouse was excluded from the 4 analysis in the rolipram 0.1 mg/kg and roflumilast 0.01 mg/kg condition, due to insufficient exploration 5 times (< 7.5 sec). One-sample t-tests showed that the d2 indices of the rolipram 0.03 mg/kg and 6 roflumilast 0.03 mg/kg conditions significantly differed from zero, indicating that mice discriminated 7 between locations of the objects after 24 h (Figure 1 ). Comparisons between rolipram conditions 8 showed significant differences (F(3,68) = 3.99, p < 0.05). Post-hoc analysis revealed that the d2 index in 9 the rolipram 0.03 mg/kg condition differed significantly from the vehicle condition (Figure 1 ). Between 10 group comparisons of the roflumilast conditions also showed significant differences (F(3,68) = 15.71, p < 11 0.001). Post-hoc analysis revealed that the d2 index of the roflumilast 0.03 mg/kg condition differed 12 significantly from the vehicle condition (Figure 1 ). 13
Subsequently, the mice were tested for spatial memory in the Y-maze. Herein, the exploration 14 time of the novel arm is quantified as a measure for spatial memory. The results for both rolipram and roflumilast on the duration of the α2-adrenergic receptor-mediated 27 anesthesia are shown in Figure 3 . One mouse was excluded because it showed the righting reflex before 28 being treated with 0.3 mg/kg roflumilast. Rolipram treatment significantly affected the duration of 29 xylazine/ketamine-induced anesthesia (F(2,33) = 8.10, p < 0.001). Post-hoc analysis showed that the 30 rolipram 0.3 mg/kg condition had a significantly reduced delay until the righting reflex compared with 31 the vehicle condition (Figure 3 ). Roflumilast conditions also differed significantly from the vehicle 32 condition (F(3,42) = 2,90, p < 0.05). Post-hoc analysis showed a reduced righting reflex delay for the 3.0 33 mg/kg roflumilast condition (Figure 3) . 34
Pharmacokinetics 35
Respectively, 0.5 h and 21 h after administration, rolipram or roflumilast and its active metabolite 36 roflumilast N-oxide were measured in the plasma and brain of the mice. 0.5 h after administration of a 37 dose of 3 mg/kg of either compound, rolipram or roflumilast and roflumilast N-oxide were readily 38 detectable in plasma and brain (Table 1) . Administration of 0.3 mg/kg of rolipram or roflumilast yielded 39 similar results, although roflumilast N-oxide was not detected in the brain anymore. However, 21 h after 40 administration, only with the high dose of 3 mg/kg, roflumilast and its metabolite were still detected 41 and in plasma only. 42 1
Combination therapy 2
First, a dose-response experiment was performed in the scopolamine-induced memory deficit model to 3 determine a sub-efficacious dose of roflumilast. No significant differences between treatment 4 conditions were observed in the level of exploration in T1 (e1: F(7,120) = 1.09, n.s.) and T2 (e2: F(7,120) 5 = 0.82, n.s.) (data not shown). One sample t-tests showed that the d2 indices of the 0.0003 to 0.03 6 mg/kg roflumilast dose conditions were significantly higher than zero, just as was the case for the 7 vehicle condition, while after scopolamine treatment the d2 index was equal to zero ( Figure 4A ). The d2 8 index was different between treatment conditions (F(3,81) = 6.67, p < 0.001) and post-hoc analyses 9
showed that the vehicle, 0.001 mg/kg, 0.003 mg/kg, 0.01 mg/kg and 0.03 mg/kg conditions had a 10 significantly higher d2 value compared to the scopolamine condition ( figure 4A ). On the other hand, only 11 the scopolamine, 0.0001 mg/kg, and 0.0003 mg/kg conditions were significantly lower compared to the 12 vehicle condition. 13
Next we tested the combination of the previously established sub-efficacious dose of roflumilast 14 and the nootropic donepezil, also at a sub-efficacious dose (0.1 mg/kg), in the scopolamine-induced 15 memory deficit model. There were no differences between treatment conditions in the level of 16 exploration in T1 (e1: F(4,115) = 0.44, n.s.) and T2 (e2: F(4,115) = 1.46, n.s.) (data not shown). One 17 sample t-tests showed that only the d2 index of the vehicle and the combination of roflumilast and 18 donepezil upon scopolamine were significantly higher than zero ( Figure 4B ). The other treatment 19 conditions showed no differences from chance performance. A significant differences in d2 between 20 treatment conditions was found (F(4,115) = 13.78, p < 0.001) and post-hoc analyses showed that the 21 vehicle and the combined treatments of roflumilast and donepezil had a significantly higher d2 index 22 when compared with scopolamine alone. At the same time, separate testing conditions of scopolamine, 23 donepezil and roflumilast were all significantly lower when compared with the vehicle condition ( Figure  24 4B). 25
Discussion
26
We found that the PDE4-I roflumilast appears equally potent (OLT) than the classic PDE4-I rolipram in 27 improving spatial memory of mice. The potential to induce emesis appears to be at least 10 times lower 28 in roflumilast when compared with rolipram. Combining sub-efficacious doses of roflumilast and 29 donepezil reversed a scopolamine-induced memory deficit of rats in the ORT. Importantly, none of the 30 compounds had any effects on exploratory activity which could have influenced memory performances. 31 32 PDE4 inhibition has been studied intensively using the PDE4-I rolipram and it was found to enhance 33 cognition in various experimental animal models including healthy, age-and pharmacologically 34 impaired, and transgenic Alzheimer mice models (for reviews see [17] [18] [19] 
roflumilast has a preferable emetic profile as emetic effects were demonstrated in fewer human 2 subjects and emesis appears to be only nausea-related without effects on vomiting [28], suggesting a 3 difference in intrinsic properties still. 4 5
When directly comparing doses of roflumilast with the PDE4-I rolipram, both compounds were equally 6 effective (0.03 mg/kg, s.c.) in improving OLT performance of mice. Interestingly, the discrimination index 7 (d2) for the roflumilast treatment group displayed an even higher absolute value compared with the 8 rolipram treatment group, indicating that roflumilast may have a stronger impact on spatial memory 9 performance. The optimal dose of rolipram was in line with previous studies [46] . The potent effect of 10 roflumilast was further confirmed by the data of the spatial Y-maze test, where the effective dose of 11 roflumilast differed significantly from vehicle at an effective dose of 0.1 mg/kg (s.c.). The same dose of 12 rolipram did not show a significant improvement in spatial memory, yet this might be prevalent with 13 higher power. 14 15
Since emesis is a side-effect of PDE4-Is in general, this measure was investigated using the 16 xylazine/ketamine induced α2-adrenergic receptor-mediated anesthesia task. Rolipram showed a strong 17 effect on emetic-like effect with a dose (0.3 mg/kg) 10 times higher than the effective dose of 0.03 18 mg/kg in the OLT. In contrast, roflumilast showed an emetic potential only at a dose (3 mg/kg) 100 times 19 the effective dose of 0.03 mg/kg in the OLT and 30 times the effective dose of 0.1 mg/kg in the spatial Y-20 maze. Based on these data, the emetic potential of roflumilast is estimated to be more than 10 times 21 lower than that of rolipram. 22 23
The dose-response study evaluated the effects of different doses of roflumilast in a memory deficit 24 model, induced by the muscarinic acetylcholine receptor antagonist scopolamine. The d2 comparisons 25 with the scopolamine condition revealed that roflumilast was able to fully restore object recognition 26 memory function in rats at doses of 0.001-0.03 mg/kg (i.p.). Whereas single sub-efficacious doses of 27 roflumilast (0.0001 mg/kg) and donepezil (0.1 mg/kg) could not reverse the scopolamine-induced deficit, 28 testing the combination of both compounds at these sub-efficacious doses completely reversed the 29 scopolamine-induced deficit. This suggest that the procognitive effects of both AChE-Is and PDE4-Is, 30 which both have dose limitations due to primarily gastrointestinal side-effects including emesis [9, 25, 31 26, 50], could be enhanced when combined at low doses. 32 33
The approximate cerebral blood volume relative to total unperfused brain volume is 0. In conclusion, PDE4 inhibition is a promising pharmacological target for treatment of cognitive deficits. 1
Roflumilast has a more optimal window for memory enhancement than rolipram since its emetic 2 potential is more than 10 times lower than that of rolipram. Roflumilast in low doses, to further avoid 3 possible emetic effects, can also be considered as a combination therapy with low doses of AChE-Is to 4 avoid the latter's gastrointestinal effects. Considering the complexity of the PDE4 family with its many 5 isoform specific subtypes, further research is needed to establish the diversity of effects on cognition, 6 but also side effect profiles including emesis. 7 8 Table 1 . Pharmacokinetics of roflumilast, roflumilast N-oxide and rolipram in the mouse
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